GSK Gets New Start For Breo With FDA Approval In Asthma
This article was originally published in The Pink Sheet Daily
FDA approved Breo Ellipta as a once-daily treatment for asthma, a new indication for a drug that has been on the market since October 2013 for COPD.
You may also be interested in...
FDA approves GlaxoSmithKline’s LABA/inhaled corticosteroid combo for asthma in adults but says more data needed in adolescents. GSK plans to throw additional promotional support behind the existing pediatric asthma claim for Advair, which is expected to face generic competition in the coming years.
The company’s five-year forecast includes the entry of Advair generics for the first time, but CEO Andrew Witty says pharma sales will nonetheless grow at low single-digits from 2016 to 2020.
The latest drug development news and highlights from our FDA Performance Tracker.